



A CD45.1<sup>+</sup> DCs → C57BL/6 mice (CD45.2<sup>+</sup>)



B CD45.2<sup>+</sup> DCs → B6.SJL mice (CD45.1<sup>+</sup>)



Supplementary Figure 1

Supplemental Figure 1: Uptake of apoptotic DCs by viable DCs in vivo. (A) CD45.1<sup>+</sup> apoptotic DCs, generated from bone marrow of B6.SJL mice were injected into C57BL/6 mice (CD45.2<sup>+</sup>). 24 hours later, gating was performed to look at viable PI<sup>-</sup>CD11c<sup>+</sup>CD45.2<sup>+</sup> host DCs among which the proportion of CFSE<sup>+</sup> cells was assessed to identify DCs that had taken up apoptotic DCs. (B) CD45.2<sup>+</sup> apoptotic DCs, generated from bone marrow of C57BL/6 mice were injected into B6.SJL mice (CD45.1<sup>+</sup>). 24 hours later, gating was performed to look at viable PI<sup>-</sup>CD11c<sup>+</sup>CD45.2<sup>+</sup> host DCs among which the proportion of CFSE<sup>+</sup> cells was assessed to identify DCs that had taken up apoptotic DCs.